Topics

Phase 3 Trial of Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority to Intravenous Formulations for HER2-Positive Breast Cancer

09:39 EDT 13 Sep 2019 | Speciality Pharma Journal

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, …

Original Article: Phase 3 Trial of Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority to Intravenous Formulations for HER2-Positive Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Phase 3 Trial of Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority to Intravenous Formulations for HER2-Positive Breast Cancer"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...